A methachromatic-based experimental model for identification of bowel as the focus of an acute inflammation


Diarrhea is the most common symptom of acute inflammation in gastrointestinal tract and the patients are isolated in order to inhibit transmission and to conduct investigations. Yet there is no standard test to distinguish gastrointestinal infection from more generalized diseases at admittance which might cause delay in therapy. Hepatocyte growth factor (HGF) is produced upon injury by mesenchymal cells. On the contrary to chronic inflammation, HGF produced in the course of acute inflammation is biologically active and shows binding affinity to heparan sulphate proteoglycan (HSPG) and dextran sulphate (DS). Based on this phenomenon, an agarose gel containing DS was prepared and immobilized on loops to investigate the feces samples for the presence or absence of growth factors such as HGF with affinity to DS. The study is conducted as a clinical evaluation of an experimental model to distinguish acute infectious gastroenteritis from other causes of diarrhea. 656 fecal samples gathered consequently from patients seeking for bowel disturbances and healthy were tested by the test and the medical reports were investigated. Upon interaction with DS, methylene blue changes color to pink. This phenomenon was inhibited by HGF and converted by addition of anti-HGF antibodies to the samples. The test distinguished acute infectious gastroenteritis with high sensitivity and specificity (96% and 92% respectively) from other causes of diarrhea. We introduce a metachromatic experimental model that might distinguish acute inflammation in alimentary tract from other causes of diarrhea. This model might be used in developing rapid diagnostic tests.

Share and Cite:

Nakka, S. , Johansson, J. , Shahzad, F. , Hanning, A. and Nayeri, F. (2013) A methachromatic-based experimental model for identification of bowel as the focus of an acute inflammation. Open Journal of Gastroenterology, 3, 42-48. doi: 10.4236/ojgas.2013.31007.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kirby, A. and Iturriza-Gómara, M. (2012) Norovirus diagnostics: Options, applications and interpretations. Expert Review of Anti-Infective Therapy, 10, 423-433. doi:10.1586/eri.12.21
[2] Holtz, L.R., Neill, M.A. and Tarr, P.I. (2009) Acute bloody diarrhea: A medical emergency for patients of all ages. Gastroenterology, 136, 1887-1898. doi:10.1053/j.gastro.2009.02.059
[3] Nakamura, T., Sakai, K. and Matsumoto, K. (2011) He patocyte growth factor twenty years on: Much more than a growth factor. Journal of Gastroenterology and Hepatology, 26, 188-202. doi:10.1111/j.1440-1746.2010.06549.x
[4] Doeppner, T.R., Kaltwasser, B., ElAli, A., Zechariah, A., Hermann, D.M. and Bahr, M. (2011) Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation. Journal of Cerebral Blood Flow Metabolism, 31, 1251-1262. doi:10.1038/jcbfm.2010.211
[5] Liedberg, B., Nylander, C. and Lundstrom, I. (1995) Biosensing with surface plasmon resonance-how it all started. Journal of Biosensors and Bioelectronics, 10, 1-9.
[6] Nayeri, F., Xu, J., Abdiu, A., Nayeri, T., Aili, D., Liedberg, B., et al. (2006) Autocrine production of biologically active hepatocyte growth factor (HGF) by injured human skin. Journal of Dermatological Sciences, 43, 49 56. doi:10.1016/j.jdermsci.2006.03.004
[7] Nayeri, F., Nayeri, T., Aili, D., Brudin, L. and Liedberg, B. (2008) Clinical impact of real-time evaluation of the biological activity and degradation of hepatocyte growth factor. Journal of Growth Factors, 26, 163-171. doi:10.1080/08977190802128083
[8] Berger, M., Welle, A., Gottwald, E., Rapp, M. and Lange, K. (2010) Biosensors coated with sulfated polysaccharides for the detection of hepatocyte growth factor/scatter factor in cell culture medium. Journal of Biosensors and Bioelectronics, 26, 1706-1709. doi:10.1016/j.bios.2010.07.065
[9] Yamaji, N., Ido, A., Moriuchi, A., Numata, M., Setoyama, H., Tamai, T., et al. (2011) Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice. Oncology Reports, 26, 335-341.
[10] Linares, P.M. and Gisbert, J.P. (2011) Role of growth factors in the development of lymphangiogenesis driven by inflammatory bowel disease: A review. Journal of Inflammatory Bowel Diseases, 17, 1814-1821. doi:10.1002/ibd.21554
[11] Cammarota, R., Bertolini, V., Pennesi, G., Bucci, E.O., Gottardi, O., Garlanda, C., et al. (2010) The tumor microenvironment of colorectal cancer: Stromal TLR-4 expression as a potential prognostic marker. Journal of Translational Medicine, 8, 112-128. doi:10.1186/1479-5876-8-112
[12] Nayeri, F., Almer, S., Brudin, L., Nilsson, I., Akerlind, B. and Forsberg, P. (2003) High hepatocyte growth factor levels in faeces during acute infectious gastroenteritis. Scandinavian Journal of Infectious Diseases, 35, 858 862. doi:10.1080/00365540310016484
[13] Bergeron, J.A. and Singer, M. (1958) Metachromasy: An experimental and theoretical reevaluation. Journal of Biophysical and Biochemical Cytology, 4, 433-457. doi:10.1083/jcb.4.4.433
[14] Fangous, M.S., Kerspern, H., Moineau, M.P., Kerlan, V., Alavi, Z. and Carre, J.L. (2012) The hook effect in calcitonin immunoradiometric assay: A case report. Annual Endocrinology Journal, 73, 552-555. doi:10.1016/j.ando.2012.07.681
[15] Pham, N.A., Morrison, A., Schwock, J., Aviel-Ronen, S., Iakovlev, V., Tsao, M.S., et al. (2007) Quantitative image analysis of immunohistochemical stains using a CMYK color model. Journal of Diagnostic Pathology, 2, 8-17. doi:10.1186/1746-1596-2-8
[16] L?nn, J., Starkhammar, J.C., K?lvegren, H., Brudin, L., Skoglund, C., Garvin, P., et al. (2012) Hepatocyte growth factor in patients with coronary artery disease and its relation to periodontal condition. Results in Immunology, 2, 7-12. doi:10.1016/j.rinim.2011.12.002
[17] L?nn, J., Shahzad, F., Uhlin, F., Bengtsson, T., Almroth, G. and Nayeri, F. (2012) High concentration but low biological activity of hepatocyte growth factor in patients with chronic renal failure. Advances in Bioscience and Biotechnology, 3, 516-523. doi:10.4236/abb.2012.324068
[18] Lonn, J., Almroth, G., Brudin, L. and Nayeri, F. (2012) An antithrombin III product containing biologically active hepatocyte growth factor may be beneficial in deep ulcer infections. Cytokine, 60, 478-486. doi:10.1016/j.cyto.2012.05.023
[19] Nayeri, F., Nilsson, I., Brudin, L. and Almer, S. (2004) Stability of faecal hepatocyte growth factor determination. Scandinavian Journal of Clinical and Laboratory Investigations, 64, 589-597. doi:10.1080/00365510410002850
[20] Nayeri, F., Aili, D., Nayeri, T., Xu, J., Almer, S., Lundstrom, I., et al. (2005) Hepatocyte growth factor (HGF) in fecal samples: Rapid detection by surface plasmon resonance. BMC Journal of Gastroenterolology, 5, 13-20. doi:10.1186/1471-230X-5-13
[21] Bean, N.H., Griffin, P.M., Goulding, J.S. and Ivey, C.B. (1990) Foodborne disease outbreaks, 5-year summary, 1983-1987. MMWR CDC Surveillance Summaries, 39, 15-57.
[22] Kostakis, I.D., Cholidou, K.G., Vaiopoulos, A.G., Vlachos, I.S., Perrea, D. and Vaos, G. (2012) Fecal calprotectin in pediatric inflammatory bowel disease: A systematic review. Journal of Digestive Diseases and Sciences, in Press. doi:10.1007/s10620-012-2347-5

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.